Table 4.
The relative to mean abundance of vaginal bacterial species that increased across gestation in pregnant women treated with placebo or probiotics.
| Placebo Group | Probiotic Group | ||||||
|---|---|---|---|---|---|---|---|
| Species | 13 Weeks | 28 Weeks | 35 Weeks | 13 Weeks | 28 Weeks | 35 Weeks | p-Value |
| Corynebacterium pseudogenitalium | −0.9 ± 1.5 a’ | 0.4 ± 1.6 b’ | 1.0 ± 1.8 c’ | −1.1 ± 1.8 a | 1.0 ± 2.4 b | 1.0 ± 1.7 b | <0.002 |
| Facklamia hominis | −1.6 ± 1.0 a’ | −1.4 ± 1.4 a’ | −0.8 ± 1.8 b’ | −1.8 ± 1.1 a | −0.9 ± 1.6 b | −1.0 ± 1.6 b | <0.004 |
| Corynebacterium amycolatum | −1.9 ± 0.9 a’ | −1.1 ± 1.5 b’ | −0.5 ± 1.8 c’ | −1.6 ± 1.0 a | −0.7 ± 1.7 b | −0.3 ± 1.1 b | <0.008 |
| Clostridiales coagulans | −1.8 ± 0.9 a’ | −1.0 ± 1.7 b’ | −0.3 ± 2.0 c’ | −1.9 ± 1.0 a | −1.3 ± 1.8 b | −1.3 ± 1.7 b | <0.003 |
| Varibaculum cambriense | −1.7 ± 1.0 a’ | −0.4 ± 1.8 b’ | 0.0 ± 1.7 b’ | −1.6 ± 1.3 a | −0.7 ± 1.5 b | −0.5 ± 1.8 b | <0.005 |
| Campylobacter ureolyticus | −2.0 ± 0.9 a’ | −1.8 ± 1.7 b’ | −1.1 ± 1.5 b’ | −1.6 ± 1.6 a | −1.6 ± 1.6 a | −1.4 ± 2.1 b | <0.004 |
| Corynebacterium coyleae | −2.2 ± 1.4 a’ | −1.1 ± 2.4 b’ | −1.4 ± 2.4 b’ | −2.1 ± 1.1 a | −1.7 ± 1.6 b | −1.7 ± 1.5 b | <0.002 |
| Prevotella disiens | −0.9 ± 1.5 a’ | 0.4 ± 1.6 b’ | 1.0 ± 1.8 b’ | −1.1 ± 1.8 a | 1.0 ± 2.4 a | 1.0 ± 1.7 a | <0.003 |
| Cryptobacterium curtum | −1.6 ± 1.0 a’ | −1.4 ± 1.4 a’ | −0.8 ± 1.8 b’ | −1.8 ± 1.1 a | −0.9 ± 1.6 a | −1.0 ± 1.6 b | <0.005 |
Results are mean values ± SD and are expressed in centered logarithm transformed ratios. Comparisons between the placebo (n = 34) and probiotic (n = 32) groups at 13, 28 and 35 weeks of gestation were assessed using the Generalized Estimation Equation model in R. Statistical significance within the probiotic group (a’, b’ and c’) and within the placebo group (a, b and c) is denoted with different letters (p < 0.05).